#1 Clinical Trials Search in Europe

Anselamimab

Anselamimab, also known as CAEL-101, is an investigational drug being studied in clinical trials for the treatment of advanced AL amyloidosis. These trials aim to evaluate the efficacy and safety of CAEL-101 in combination with standard plasma cell dyscrasia treatment for patients with Mayo Stage IIIa and IIIb cardiac AL amyloidosis. The studies focus on improving overall survival, reducing cardiovascular hospitalizations, and enhancing quality of life for patients with this challenging condition.

Table of Contents

What is ANSELAMIMAB?

ANSELAMIMAB, also known as CAEL-101, is an investigational medication being developed for the treatment of advanced AL amyloidosis[1][2]. It is a protein-based drug that is administered through intravenous infusion, meaning it’s given directly into the bloodstream through a vein.

Target Condition: AL Amyloidosis

AL amyloidosis is a rare and serious condition where abnormal proteins build up in various organs, particularly the heart. The “AL” stands for “amyloid light chain,” referring to the type of protein involved. In the clinical trials, ANSELAMIMAB is being studied specifically for patients with stage IIIa and IIIb cardiac AL amyloidosis[1][2]. These are advanced stages of the disease where the heart is significantly affected, leading to severe symptoms and reduced life expectancy.

How ANSELAMIMAB Works

While the exact mechanism isn’t detailed in the trial information, ANSELAMIMAB is designed to target and potentially remove the amyloid deposits that accumulate in organs, particularly the heart. By doing so, it aims to improve organ function and overall patient survival[1][2].

Clinical Trials

ANSELAMIMAB is currently being evaluated in two Phase 3 clinical trials:

  1. A study for patients with stage IIIa AL amyloidosis[1]
  2. A study for patients with stage IIIb AL amyloidosis[2]

Both trials are designed to test ANSELAMIMAB in combination with standard treatments for the underlying plasma cell disorder that causes AL amyloidosis. The studies are “double-blind,” meaning neither the patients nor the doctors know who is receiving ANSELAMIMAB or a placebo, which helps ensure unbiased results.

Potential Benefits

The clinical trials aim to determine if ANSELAMIMAB can provide the following benefits[1][2]:

  • Improved overall survival
  • Reduced frequency of heart-related hospitalizations
  • Improved heart function (measured by various tests)
  • Better quality of life
  • Increased physical function (measured by a walking test)

Safety and Side Effects

As ANSELAMIMAB is still in clinical trials, its full safety profile is not yet known. The studies are carefully monitoring for any side effects or adverse reactions. Patients in the trials will be closely observed for changes in vital signs, weight, laboratory test results, and heart activity (via ECG)[1][2].

Eligibility for Treatment

The clinical trials have specific criteria for who can participate. Generally, eligible patients[1][2]:

  • Have confirmed AL amyloidosis with significant heart involvement
  • Have not received prior treatment for AL amyloidosis
  • Meet certain blood test criteria indicating the presence of abnormal protein levels
  • Do not have other forms of amyloidosis or multiple myeloma

It’s important to note that these criteria are for the clinical trials. If ANSELAMIMAB is approved in the future, the eligibility for treatment may be different.

Future Prospects

ANSELAMIMAB is still an investigational drug, meaning it’s not yet approved for general use. The results of these Phase 3 trials will be crucial in determining whether it becomes available as a treatment option for patients with advanced AL amyloidosis. If successful, ANSELAMIMAB could provide a much-needed new therapy for this serious condition[1][2].

Aspect Details
Drug Name Anselamimab (CAEL-101)
Trial Phase Phase 3
Target Condition Mayo Stage IIIa and IIIb cardiac AL amyloidosis
Primary Objectives Improve overall survival, reduce cardiovascular hospitalizations
Treatment Combination CAEL-101 with standard plasma cell dyscrasia treatment (CyBorD-based regimen)
Key Eligibility Criteria Newly diagnosed, treatment-naïve patients with confirmed AL amyloidosis and cardiac involvement
Primary Endpoints Time to all-cause mortality, frequency of cardiovascular hospitalizations
Secondary Endpoints Quality of life measures, cardiac function improvements, functional capacity
Safety Assessments Adverse events, vital signs, laboratory tests, ECGs
Administration Route Intravenous infusion

FAQ

  • What is AL amyloidosis? AL amyloidosis is a rare disease where abnormal proteins called amyloids build up in organs, particularly the heart. It's caused by a disorder in plasma cells, which produce these abnormal proteins. In cardiac AL amyloidosis, the heart is significantly affected, leading to heart failure symptoms.
  • What is Anselamimab (CAEL-101)? Anselamimab, also known as CAEL-101, is an investigational drug being studied for the treatment of AL amyloidosis. It's designed to target and remove the amyloid deposits that accumulate in organs, particularly the heart, in patients with this condition.
  • Who is eligible for these clinical trials? The trials are for patients with newly diagnosed Mayo Stage IIIa or IIIb cardiac AL amyloidosis who have not received prior treatment. Participants must have measurable disease, confirmed AL amyloidosis diagnosis, and cardiac involvement. Specific criteria, including NT-proBNP levels, are used to determine eligibility.
  • What are the main goals of these clinical trials? The primary objectives are to determine if CAEL-101, when combined with standard treatment, can improve overall survival and reduce the frequency of cardiovascular hospitalizations in patients with advanced AL amyloidosis. The trials also aim to evaluate the safety and tolerability of CAEL-101.
  • How is the effectiveness of CAEL-101 measured in these trials? The effectiveness is measured through various endpoints, including overall survival, frequency of cardiovascular hospitalizations, changes in quality of life scores (KCCQ-OS and SF-36v2 PCS), improvements in heart function (NT-proBNP levels and global longitudinal strain), and physical function (six-minute walk test).

Ongoing Clinical Trials on Anselamimab

  • Study on the Effectiveness and Safety of CAEL-101 with Drug Combination for Patients with Advanced AL Amyloidosis

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia France Germany Greece +3

  • Study on the Effectiveness and Safety of CAEL-101 with Plasma Cell Dyscrasia Treatment in Patients with Stage IIIa AL Amyloidosis

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Czechia France Germany Greece Italy +2

Glossary

  • AL amyloidosis: A rare disease where abnormal proteins called amyloids, produced by disordered plasma cells, build up in organs, particularly the heart, leading to organ dysfunction.
  • Anselamimab (CAEL-101): An investigational drug designed to target and remove amyloid deposits in organs affected by AL amyloidosis.
  • Mayo Stage IIIa and IIIb: Advanced stages of cardiac involvement in AL amyloidosis, determined by biomarker levels (particularly NT-proBNP) and indicating severe heart damage.
  • Plasma cell dyscrasia (PCD): A group of disorders characterized by the abnormal production of plasma cells, which in AL amyloidosis leads to the production of harmful amyloid proteins.
  • NT-proBNP: N-terminal pro-brain natriuretic peptide, a biomarker used to assess heart function and determine the severity of cardiac involvement in AL amyloidosis.
  • Global longitudinal strain (GLS%): A measure of heart muscle function, used to assess improvements in cardiac performance during treatment.
  • Six-minute walk test (6MWT): A test measuring the distance a patient can walk in six minutes, used to assess functional capacity and response to treatment.
  • KCCQ-OS: Kansas City Cardiomyopathy Questionnaire Overall Score, a tool used to measure quality of life in patients with heart conditions.
  • SF-36v2 PCS: Short Form 36 Health Survey Physical Component Score, a questionnaire used to assess overall physical health and quality of life.
  • Cardiovascular hospitalization (CVH): Hospital admissions related to heart problems, a key measure of disease progression and treatment effectiveness in cardiac AL amyloidosis.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-cael-101-with-plasma-cell-dyscrasia-treatment-in-patients-with-stage-iiia-al-amyloidosis/
  2. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-cael-101-with-drug-combination-for-patients-with-advanced-al-amyloidosis/